Tatyana Feldman, MD

Articles by Tatyana Feldman, MD

Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL

ByTatyana Feldman, MD,Denise Zou, MA,Mayvis Rebeira, PhD,Joseph Lee, PhD,Michelle Fanale, MD,Thomas Manley, MD,Shangbang Rao, PhD,Joseph Feliciano, PharmD,Mack Harris, BA,Anuraag Kansal, PhD

February 11th 2020

An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).

Latest Updated Articles

Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL
February 11th 2020

Tatyana Feldman, MD

Articles by Tatyana Feldman, MD

Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL

Latest Updated Articles

Trending on AJMC

Special Report: The Oncology Care Model, 10 Years Later

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD